Regeneron Pharmaceuticals (REGN) Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.

Which has more volatility & risk, REGN or AMGN?

Regeneron Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Which has stronger valuation & earnings, REGN or AMGN?

Regeneron Pharmaceuticals has higher earnings, but lower revenue than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.20B	5.09	$4.41B	$38.28	17.27
Amgen	$33.42B	5.05	$4.09B	$7.55	41.64

Is REGN or AMGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%
Amgen	12.24%	176.32%	11.71%

Do insiders and institutionals have more ownership in REGN or AMGN?

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is REGN or AMGN a better dividend stock?

Regeneron Pharmaceuticals pays an annual dividend of $0.88 per share and has a dividend yield of 0.1%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.0%. Regeneron Pharmaceuticals pays out 2.3% of its earnings in the form of a dividend. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the MarketBeat Community favor REGN or AMGN?

Amgen received 3 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.87% of users gave Amgen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Regeneron Pharmaceuticals	Outperform Votes 1548 66.93%	Underperform Votes 765 33.07%
Amgen	Outperform Votes 1551 71.87%	Underperform Votes 607 28.13%

Does the media refer more to REGN or AMGN?

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 52 mentions for Amgen and 35 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.53 beat Regeneron Pharmaceuticals' score of 1.43 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	32 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	51 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts rate REGN or AMGN?

Regeneron Pharmaceuticals currently has a consensus target price of $973.13, indicating a potential upside of 47.22%. Amgen has a consensus target price of $314.04, indicating a potential downside of 0.11%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.76
Amgen	2 Sell rating(s)	10 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Regeneron Pharmaceuticals beats Amgen on 12 of the 22 factors compared between the two stocks.